M. Chiesa

Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives.

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2017, International review of cell and molecular biology.

TITLE: CIRCULATING IMMUNE BIOMARKERS IN PERIPHERAL BLOOD CORRELATE WITH CLINICAL OUTCOMES IN ADVANCED BREAST CANCER.

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021 .

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study

F. Rojo, R. Andrés, V. Sánchez-Margalet, 2021, Cancers.

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

F. Rojo, M. Ramos, R. Caballero, 2022, BMC Cancer.

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021, Scientific Reports.

New horizons in breast cancer: the promise of immunotherapy

V. Sánchez-Margalet, L. de la Cruz-Merino, M. Chiesa, 2018, Clinical and Translational Oncology.

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

J. Herranz, J. Albanell, L. Gianni, 2022, Frontiers in Oncology.

Publisher Correction: Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

F. Rojo, V. Sánchez-Margalet, R. Caballero, 2021, Scientific Reports.